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TEER, FITC-dextranWe previously demonstrated that dengue virus (DENV) nonstructural 4B protein (NS4B) induced dengue
hemorrhagic fever (DHF)-associated immunomediators in THP-1 monocytes. Moreover, cleavage of NS4AB
polyprotein by the NS2B3 protease, signiﬁcantly increased immunomediator production to levels found
after DENV infection. In this report using primary human microvascular endothelial cells (HMVEC) transwell
permeability model and HMVEC monolayer, we demonstrate that the immunomediators secreted in the
supernatants of DENV-infected monocytes increase HMVEC permeability and expression of ICAM-1, VCAM-1
and E-selectin. Moreover, maturation of NS4B via cleavage of 2KNS4B is sufﬁcient to induce immunomediators
that cause HMVEC phenotypic changes, which appear to be synergistically induced by TNFα and IL-8. These
data suggest that therapies targeting the maturation steps of NS4B, particularly 2KNS4B processing, may reduce
overall DHF-associated immunomediator levels, thereby reducing DHF-associated morbidity and mortality.
Alternatively, TNFα inhibitors may be a valid intervention strategy during the later stages of infection to
prevent DHF progression.
© 2011 Elsevier Inc. All rights reserved.Introduction
Dengue virus (DENV) causes substantial human morbidity and
mortality worldwide infecting an estimated 50–100 million people
annually and causing over 500,000 hospitalizations (World Health
Organization, 2009). Approximately 10% of patients presenting with
classic dengue fever (DF) progress to severe dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS), which may lead to death
(Malavige et al., 2004; WHO, 1997). DHF/DSS mortality rates average
5%, with approximately 25,000 deaths each year (World Health
Organization, 1997). Although mechanisms leading to DHF/DSS are
unclear, an indisputable characteristic of severe dengue disease is
plasma leakage resulting from vascular endothelial cell activation,
as measured by adhesion molecules expression and increased vascu-
lar cell permeability (Chang et al., 1990; Khongphatthanayothin
et al., 2006; Koraka et al., 2004; Srichaikul and Nimmannitya, 2000;
Srikiatkhachorn, 2009). Clinical evidence suggests that plasma leakagehn A. Burns School of Medicine,
Fax: +1 808 692 1984.
).
rights reserved.progresses rapidly after peak viremia and defervescence when elevated
levels of chemokines and cytokines exist in the periphery (Braga et al.,
2001; Libraty et al., 2002; Murgue, 2010; Raghupathy et al., 1998;
Vaughan et al., 2008; Vitarana et al., 1991).
There is little evidence that DENV infects vascular endothelial cells
in patients progressing to DHF/DSS (Halstead, 1989). DENV antigens
have been demonstrated in lung endothelial cells collected at post-
mortem (Jessie et al., 2004) and DENV replicates efﬁciently in
human endothelial cells in-vitro (Anderson et al., 1997; Andrews et
al., 1978; Arevalo et al., 2009; Avirutnan et al., 1998; Bonner and
O'Sullivan, 1998; Bunyaratvej et al., 1997; Chen et al., 2009; Huang
et al., 2000; Warke et al., 2003). However, the signiﬁcance of DENV-
infected endothelial cells during DHF pathogenesis remains inconclu-
sive due to the scarcity of human autopsy studies and the timing of
specimen collection. Moreover, endothelial cells treated in-vitro with
the supernatants from DENV-infected monocytes or monocyte-
derived macrophages increase expression of adhesion molecules and
permeability, respectively, while direct infection of endothelial cells
does not alter either phenotype (Anderson et al., 1997; Bonner and
O'Sullivan, 1998; Carr et al., 2003; Chareonsirisuthigul et al., 2007), sug-
gesting that the elevated immunomediators in DHF/DSS patients are
327J.F. Kelley et al. / Virology 422 (2012) 326–337primarily responsible for modulating endothelial cell adhesion mole-
cules and thereby cell permeability.
Other reports suggest that DENV preferentially infects periph-
eral blood monocytes which contribute to the overproduction of
immunomediators detected during severe dengue disease (Durbin
et al., 2008). Additionally, DENV-infected primary human mono-
cytes secrete high levels of DHF/DSS-associated immunomediators
(Chareonsirisuthigul et al., 2007; Ubol et al., 2008). We previously
reported that DENV nonstructural 5 protein (NS5), NS4B or matura-
tion of NS4B via cleavage of 2KNS4B increased the secretion of IL-6,
IL-8, TNFα, and IP-10 in THP-1 monocytic cell line (Kelley et al.,
2011). Similarly, other investigators have demonstrated that IL-6,
IL-8 or TNFα is primarily responsible for initiating and sustaining
increased vascular endothelial cell permeability (Carr et al., 2003;
Petreaca et al., 2007; Raghupathy et al., 1998) whereas TNFα and
IL-1β are the primary stimulatory molecules for intercellular adhe-
sion molecule 1 (ICAM-1), vascular cell adhesionmolecule-1 (VCAM-1)
and E-selectin (E-sel) (Anderson et al., 1997; Cardier et al., 2005;
Detmar et al., 1992; Wyble et al., 1996). Currently, animal models are
inadequate to study DENV immunopathogenesis and in-vitro studies
examining adhesion molecule expression and permeability vary due
to their inconsistent use of macro- andmicro-vascular endothelial cells.Fig. 1. Optimization of the in-vitro HMVEC permeability model. (A) Transwell® 24-well i
seeding 100,000 HMVEC cells and incubated with 250 μL and 2 mL of media in the upper
TEER, presented asΩ/cm2, and the percent FITC-dextran crossing the HMVEC/PET membran
tightness was observed on day 6 after seeding when the TEER was above 200 Ω/cm2 and le
point, day 6 after seeding, chosen to start treatment of the HMVEC permeability mode
permeability, either 250 μL of 0.5 ng/mL TNFα (125 pg total) or 2.5 ng/mL of IL-8 (625 pg
6 after seeding and TEER and FITC-dextran assay was conducted every day. Data are p
measure permeability was found to be 24 h after treatment. Bars represent the mean±In this report, we demonstrate that TNFα and IL-8 are the primary
vasoactive mediators produced from DENV-infected THP-1monocytic
cells. Importantly, cleavage of 2KNS4B during NS4B maturation is
sufﬁcient to induce TNFα and IL-8, which may synergistically induce
phenotypic changes in primary human microvascular endothelial
cells (HMVEC). We also demonstrate that membrane permeability
changes directly correlate with increased expression of VCAM-1 and
E-sel. Overall, these data provide a partial explanation for the source
of DENV-induced, monocyte-derived vasoactive mediators. Moreover,
the increased HMVEC permeability and expression of adhesion mole-
cules are primarily via an indirect route, requiring the participation of
virus-infected monocytes, speciﬁcally expression of 2KNS4B, rather
than virus-infected endothelial cells.Results
Immunomediators secreted in the supernatants of DENV-infected THP-1
monocytes increase HMVEC adhesion molecules and permeability
We previously demonstrated that DENV-infected THP-1 cells signif-
icantly increased the secretion of IP-10, TNFα, IL-6 and IL-nserts with PET membranes either with or without ﬁbronectin coating were used for
and lower chambers, respectively. (B) To determine the optimal treatment window,
es weremeasured every day for 15 days after seeding cells. Themaximummembrane
ss than 4% of FITC-dextran crossed the membrane. Therefore, (*) represents the time
l. (C) To determine the optimal incubation period and end point time to measure
total) was incubated with the PET-ﬁbronectin/HMVEC membrane beginning on day
resented as percent of non-treated control membranes. The optimal time point to
SD of two independent experiments conducted in triplicate.
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whether the immunomediators secreted in the aforementioned super-
natants could increase HMVEC adhesion molecules or permeability,
we optimized the in-vitro HMVEC transwell permeability model. The
HMVECmodel was constructed with Transwell® 24-well inserts con-
sisting of a PET/ﬁbronectin membrane layered with primary HMVEC
(Fig. 1A). To measure permeability, we implemented both trans-
endothelial electrical resistance (TEER) and FITC-dextran permeabil-
ity assays as previously described by us and other investigators
(Bonner and O'Sullivan, 1998; Carr et al., 2003; Dewi et al., 2008;
Petreaca et al., 2007; Verma et al., 2009). We observed that HMVEC
seeded on PET membranes pretreated with ﬁbronectin provided
more effective membrane integrity than the PET membranes with-
out ﬁbronectin and the ideal treatment window for our experiments
was between days 6 and 10 after HMVEC seeding (Fig. 1B). An in-
creased TEER reading of approximately 200 Ω/cm2 corresponded
with a decreased FITC-dextran reading of approximately 2% crossing
for each time point from days 6 to 10 (Fig. 1B), indicating sustained
HMVEC integrity. Given that TNFα and IL-8 increase permeability
(Dewi et al., 2004; Jacobs and Levin, 2002; Petreaca et al., 2007;
Talavera et al., 2004) and to determine optimal control and incuba-
tion times, we tested both mediators as positive controls. We ob-
served that TNFα (0.05 ng/mL) and IL-8 (2.5 ng/mL) consistently
increased cell permeability. Maximum permeability occurred at
24 h after treatment wherein TNFα and IL-8 altered TEER to approx-
imately 50% and 25% of controls, respectively (Fig. 1C). The same
concentrations of TNFα and IL-8 increased FITC-dextran crossingFig. 2. Supernatants from DENV-infected THP-1 cells increase HMVEC adhesion molecules a
in HMVEC treated for 16 h with supernatants from control or infected THP-1 cells collected
positive controls, HMVEC were treated for 16 h with the supernatants from LPS treated THP
control. (B) Western blot analysis of ICAM-1, VCAM-1 and E-sel expression on HMVEC mon
DENV-infected THP-1 cells. The control supernatants are from mock-infected (UV-treated D
both collected at day 1 and day 3 after infection. As a positive control, HMVEC were treate
determine the permeability potential of DENV-infected THP-1 supernatants, TEER and FIT
the materials and methods section. Before treatment, supernatants were UV-treated to ina
treated THP-1 cells were used. Data are presented as percent of non-treated control memb
(*) indicates statistical signiﬁcance at pb0.05 as compared to controls.the membrane to almost 400% and 150% of controls, respectively.
As expected, after removal of TNFα and IL-8 and washing with buff-
er, a full recovery of membrane integrity was observed after an addi-
tional 24 h of incubation with only culture media (Fig. 1C).
To better understand the kinetics of DENV-induced HMVEC phe-
notypic changes, we initially tested the supernatants from DENV-
infected THP-1 cells for increases in ICAM-1, VCAM-1 and E-sel
expression and permeability. The supernatants were UV-treated to
inactivate infectious virus (Verma et al., 2009) and incubated with
HMVEC monolayers for 16 h as previously described (Anderson et
al., 1997). We demonstrated using qRT-PCR that VCAM-1 and E-sel
mRNA transcript levels increased 10- and 30-fold, respectively, but
ICAM-1 mRNA did not signiﬁcantly increase at 16 h (Fig. 2A). Also,
we demonstrated by western blot that supernatants collected at
days 1 and 3 after infection induced VCAM-1 and E-sel compared to
the supernatants from mock-infected THP-1 control cells, similar to
mRNA expression patterns (Fig. 2B). The observed level of ICAM-1
protein expression remained unchanged at 16 h after treatment
(Fig. 2B). Given that other investigators have demonstrated ICAM-1
expression on HMVEC cells (Detmar et al., 1992), we conducted a
time point experiment, incubating HMVEC with 200 pg of IL-1β, based
on detected serum levels in DHF patients, as previously described
(Bozza et al., 2008; Kuno and Bailey, 1994; Molet et al., 1998). We
observed by western blot that expression of ICAM-1 peaked at 8 h
after incubation with IL-1β (Supplemental Fig. 1A). Indeed, when
we incubated HMVEC with the supernatants from DENV-infected
THP-1 cells for 8 h, we observed an increase in the expression ofnd permeability. (A) qRT-PCR analysis of ICAM-1, VCAM-1 and E-sel mRNA fold-change
at day 1 (D1 Sup) and day 3 (D3 Sup) after infection or 24 h after LPS treatment. As
-1 cells or incubated directly with 200 pg of IL-1β. GAPDH was used as the endogenous
olayers seeded on 12-well culture plates and treated for 16 h with supernatants from
ENV) THP-1 cells while the infected supernatants are from DENV-infected THP-1 cells
d directly with 200 pg of IL-1β and β-actin was used as an endogenous control. (C) To
C-dextran crossing the PET membrane were determined as described in Fig. 1 and in
ctivate viable virus. As positive controls, 0.5 ng/mL of TNFα or supernatants from LPS
ranes and bars represent the mean±SD of two independent experiments in triplicate.
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natants from DENV-infected THP-1 cell collected at day 1 after
infection signiﬁcantly increased HMVEC permeability at 24 h after
incubation whereas day 3 supernatants initiated permeability more
rapidly and to higher levels, signiﬁcantly increasing at 16 and 24 h
after incubation as measured by TEER and FITC-dextran crossing
the PET/HMVEC membrane (Fig. 2C). Moreover, we demonstrated
no signiﬁcant differences in HMVEC viability for up to 2 days after
treatment with TNFα, IL-8, supernatants from THP-1 cells incubated
with LPS or direct infection with DENV (Supplemental Fig. 2). Taken
together, these data suggest that the immunomediators present in
supernatants of DENV-infected THP-1 cells increase HMVEC adhesion
molecules and this induction corresponds with increased permeability
at 16 and 24 h.
DENV-infected HMVEC do not increase expression of ICAM-1, VCAM-1 or
E-sel nor increase permeability levels
Humanendothelial cells are susceptible toDENV infection (Andrews
et al., 1978; Arevalo et al., 2009). However, other investigators have
demonstrated that DENV-infected endothelial cells in-vitro do not
increase permeability (Bonner and O'Sullivan, 1998; Dewi, Takasaki,
and Kurane, 2004) or expression of adhesion molecules (Anderson
et al., 1997). Since we demonstrated HMVEC phenotypic changes
upon treatment with UV-treated supernatants from DENV-infected
THP-1 cells, we wanted to ensure that DENV infection per se does
not lead to the observed HMVEC phenotypic changes. Therefore,
we infected HMVEC monolayers with DENV MOI-1 and measured
DENV replication kinetics by plaque assay and qRT-PCR. On day 3Fig. 3. DENV-infected HMVEC do not increase expression of adhesion molecules or permea
as described in Fig. 2 and were infected with DENV-2 NGC strain at an MOI-1 to eval
(A) HMVEC or Vero cells were infected with DENV with an MOI-1 and cells and supern
numbers were determined by plaque assay and qRT-PCR, respectively, on samples collec
blot analysis of DENV envelope, ICAM-1, VCAM-1 and E-sel expression levels on mock-in
positive control, HMVEC were treated directly with 200 pg of IL-1β for 8 h (ICAM-1) or 16 h (
of ICAM-1, VCAM-1 and E-selmRNA fold-change inDENV-infectedHMVEC compared to same ti
with 200 pg of IL-1β for 8 h (ICAM-1) or 16 h (VCAM-1 and E-sel) are positive controls and G
membranes and infected with DENV. The percent change of TEER (solid line) and FITC-dextra
represent the mean±SD of at least six samples.after infection, maximum viable virus released was log 5 PFU/mL and
copy numbers reached approximately log 7 viral RNA transcripts/μg of
RNA (Fig. 3A). Given that other investigators have demonstrated that
DENV-infected large vessel human umbilical vein endothelial cells
(HUVEC) increase IL-6 and IL-8 expressions, which may regulate
adhesion molecule expression via autocrine induction, we assessed
using the Luminex® multiplex technology whether DENV-infected
HMVEC increased the production of immunomediators. On or before
day 3 after infection of HMVEC with DENV, IL-6 (115 pg/mL, p=0.12)
and IL-8 (852 pg/mL, p=0.09) levels were slightly increased compared
to control cells (85 pg/mL and 634 pg/mL, respectively), but these
increases were not statistically signiﬁcant (Table 1). Importantly,
we did not detect TNFα or IFNγ in the supernatants from either mock-
infected control or DENV-infected HMVEC. As demonstrated by western
blot, the expression of DENV envelope gene was detected at 16 and
24 h after infection. However, ICAM-1, VCAM-1 and E-sel protein
expression did not increase at 8, 16 or 24 h after infection (Fig. 3B).
These data were conﬁrmed by qRT-PCR wherein ICAM-1, VCAM-1 and
E-sel mRNA transcript changes in DENV-infected HMVEC were below
the 2-fold cutoff relative to controls at 8, 16, 24, and 48 h after infection
(Fig. 3C). To determine if DENV-infectedHMVEC increased permeability,
we infected HMVEC with DENV MOI-1 directly on the transwell per-
meability model and measured TEER and FITC-dextran crossing the
membrane. We observed no signiﬁcant permeability changes for
up to 72 h after infection (Fig. 3D) even though we demonstrated
by plaque assay data a steady increase in viable virus released
from the infected permeability model, reaching approximately log
4 PFU/mL at 72 h after infection (data not shown). Overall, these data
suggest that DENV infection per se does not modulate HMVECbility. HMVEC cells were seeded on 12-well culture plates or 24-well Transwell inserts
uate replication kinetics, adhesion molecule expression and permeability changes.
atants were collected each day for four consecutive days. Viral titers and RNA copy
ted each day after infection (HMVEC, solid line; Vero cells, dotted line). (B) Western
fected and DENV-infected HMVEC harvested at 8, 16, and 24 h after infection. As a
VCAM-1 and E-sel) and β-actin was used as an endogenous control. (C) qRT-PCR analysis
me point controls harvested at 8, 16, 24 and 48 h after infection. HMVECdirectly incubated
APDH was used as the endogenous control. (D) HMVEC were seeded on PET-ﬁbronectin
n crossing the membrane (dotted line) was measured for up to 72 h after infection. Bars
Table 1
Immunomediators detected in the supernatants of DENV-infected primary HMVEC
cells.
IFNγ TNFα IL-6 IL-8
Meana SDb Mean SD Mean SD Mean SD
8 h control supernatantd NDc – ND – 61 8.9 571 113
8 h DENV supernatante ND – ND – 84 12 691 146
Day 1 control supertanantd ND – ND – 86 26 621 106
Day 1 DENV supertanante ND – ND – 104 35 893 135
Day 3 control supertanantd ND – ND – 85 10 634 99
Day 3 DENV supernatante ND – ND – 115 19 852 116
a pg/mL; n≥4 samples from at least 2 experiments.
b SD = standard deviation.
c ND = not detected.
d Supernatant from HMVEC cells infected with UV-treated DENV NGC at MOI 1.
e Supernatant from HMVEC cells infected with DENV NGC at MOI 1.
330 J.F. Kelley et al. / Virology 422 (2012) 326–337adhesionmolecule expression or alter the HMVEC phenotype based
on the permeability assay. However, the immunomediators secret-
ed in the supernatants from DENV-infected THP-1 monocytes are
primarily responsible for the observed phenotypic changes.Maturation of NS4B in THP-1 monocytes induces immunomediators
sufﬁcient to alter HMVEC adhesion molecules and permeability
We previously demonstrated that maturation of NS4B, via cleav-
age of 2KNS4B by host proteases, signiﬁcantly enhanced the produc-
tion of immunomediators compared to levels induced by NS5, which
also signiﬁcantly induced immunomediators compared to the V5
vector control (Kelley et al., 2011). Using the Luminex® multiplex
technology, we quantitated immunomediators secreted in the su-
pernatants of THP-1 cells expressing DENV NS proteins (Table 2).
Given that immunomediator levels found in the supernatants of
THP-1 cells expressing 2KNS4B were signiﬁcantly elevated (Supple-
mental Table 1), we expected that supernatants from THP-1 cells
expressing 2KNS4B would modulate HMVEC adhesion molecules
and permeability. Using HMVEC monolayers, we demonstrated that
the supernatant from THP-1 cells expressing NS4B, 2KNS4B or NS5
signiﬁcantly induce ICAM-1 (8 h after treatment), and VCAM-1 and
E-sel (16 h after treatment)mRNA transcripts relative to levels induced
by the supernatants from THP-1 cells expressing the V5 control vector
(Fig. 4A). Supernatants from monocytes expressing 2KNS4B induced
maximum levels of ICAM-1, VCAM-1 and E-sel reaching 8-, 11- and
23-fold respectively relative to the V5 control, which were signiﬁ-
cantly higher than levels induced by the supernatant from THP-1Table 2
Immunomediators present in the supernatants of THP-1 cells expressing DENV NS proteins
IFNγ VEGF
Meana SDb Mean SD Mean
No pDNA supernatantc 1.7 0.5 17 4.7 13
V5 supernatantd 1.5 0.4 18 6.4 14
NS3B3(pro) supernatantd 1.8 0.2 22 1.4 10
NS3 supernatantd 1.4 0.4 18 7.1 12
NS4AB supertanantd 1.3 0.6 20 3.5 9.6
NS4B supernatantd 3.4 1.2 19 13 44⁎
2KNS4B supertanantd 6.5⁎ 0.7 46 11 65⁎
NS5 supernatantd 5.6⁎ 1.0 40 14 59⁎
LPS supernatant 6.2 0.9 20 8.9 63
a pg/mL; n≥6 samples from at least 3 experiments.
b SD = standard deviation.
c Supernatant from THP-1 cells electroporated without pDNA.
d Supernatant from THP-1 cells electroporated with speciﬁed pDNA.
⁎ Statistical signiﬁcance (pb0.05) compared to V5 pDNA control.
§ Statistical signiﬁcance (pb0.05) compared to NS5 pDNA sample.cells expressing NS4AB (pb0.05) (Fig. 4A). Western blot data con-
ﬁrmed that the supernatants from THP-1 cells expressing 2KNS4B
or NS5 increased ICAM-1, VCAM-1 and E-sel protein expression com-
pared to the supernatant from THP-1 cells expressing V5 or NS4AB
proteins (Fig. 4B). When we tested for permeability changes, we ob-
served that the supernatants from THP-1 cells expressing 2KNS4B sig-
niﬁcantly increased permeability compared to the supernatant
from NS4AB at 16 and 24 h after treatment using both TEER and
FITC-dextran assays, by approximately 25% and 140% compared to
controls, respectively (Fig. 4C). Overall, we demonstrate that matu-
ration of NS4B via cleavage of 2KNS4B in THP-1 cells is capable of
inducing a signiﬁcant quantity of immunomediators, which induce
the expression of HMVEC adhesion molecules and permeability.TNFα and IL-8 synergistically modulate HMVEC adhesion molecules and
permeability
TNFα effectively increases the expression of ICAM-1, VCAM-1 and
E-sel in HUVEC (Anderson et al., 1997). Moreover, TNFα at concentra-
tions ranging from 10 pg/mL to 10 μg/mL (Carr et al., 2003; Dewi,
Takasaki, and Kurane, 2004; Gibbs et al., 1990; Marcus et al., 1996;
Nooteboom et al., 2000) and IL-8 at concentrations ranging from
50 ng/mL to 1 μg/mL (Bifﬂ et al., 1995; Petreaca et al., 2007) can modu-
late endothelial cell permeability depending on the permeability model
used for the assay. In contrast, Beynon and colleagues have demon-
strated that low concentrations of immunomediators in combina-
tion synergistically alter adhesion molecules and permeability when
compared to addition of individual recombinant chemokines or cyto-
kines (Beynon et al., 1993). Since the supernatants from THP-1 cells
infected with DENV or expressing individual NS proteins consist of an
array of immunomediators, we hypothesized that TNFα and IL-8modu-
late adhesionmolecule changes or permeability. To test this hypothesis,
we incubated the supernatant of DENV infected or transfected THP-1
cells with neutralizing antibodies against TNFα and IL-8 prior to incu-
bating the supernatantwithHMVEC. Of note, using Luminex technology
we demonstrated that in the neutralizing antibodies treated superna-
tants, the levels of TNFα and IL-8 were in the nondetectable range: 0.2
and 0.3 pg/mL for TNFα and IL-8, respectively. Upon neutralizing
IL-8 in the supernatants from THP-1 cells expressing 2KNS4B and
incubation on HMVEC, we observed using western blot that there
was no reduction of HMVEC adhesion molecule expression levels
compared to the effects caused by the supernatants without neu-
tralizing IL-8 antibodies (Figs. 5A,B). However, we did observe a slight
reduction in TEER or FITC-dextran crossing the permeability membrane
but the changes were not signiﬁcant (Fig. 5C). When we neutralized.
IP-10 TNFα IL-6 IL-8
SD Mean SD Mean SD Mean SD
3.9 4.4 1.8 1.9 0.7 241 116
5.6 5.3 3.8 2.5 1.4 202 65
6.2 11 7.8 2.8 0.9 218 145
7.1 14 7.3 2.2 0.6 218 145
6.4 12 5.6 2.3 0.4 229 91
9.7 27 9.5 57⁎ 17 1100⁎ 449
15 30 13 185§ 36 2413§ 382
13 29 11 109⁎ 30 1513⁎ 393
9.9 115 12 223 19 3109 267
Fig. 4. Immunomediators secreted by THP-1 cells expressing 2KNS4B or NS5 proteins promote endothelial cell activation and permeability. (A) qRT-PCR analysis of ICAM-1,
VCAM-1 and E-sel mRNA fold-change from HMVEC after treatment with supernatants from THP-1 cells expressing DENV NS2B3(pro), NS3, NS4AB, NS4B, 2KNS4B or NS5 or
incubated with 200 pg of IL-1β. Values for ICAM-1 (8 h after treatment) and VCAM-1 and E-sel (16 h after treatment) are normalized to expression levels induced by
supernatants from THP-1 cells expressing V5 control epitope. GAPDH is the endogenous control and (*) indicates statistical signiﬁcance at pb0.05 as compared to values
determined for NS4AB. (B) Western blot analysis of ICAM-1, VCAM-1 and E-sel on HMVEC after treatment with supernatants from THP-1 cells expressing DENV NS4AB,
2KNS4B or NS5 or V5 control. HMVEC were harvested at 8 h (ICAM-1) or 16 h (VCAM-1 and E-sel) after treatment. As a positive control, HMVEC were treated directly with
200 pg of IL-1β and β-actin is shown as the endogenous control. (C) HMVEC were seeded on PET-ﬁbronectin membranes and incubated with supernatants described in
Fig. 3A. The percent change of TEER and FITC-dextran crossing the membrane was measured for supernatant from THP-1 cells expressing NS4AB, 2KNS4B and NS5. The
supernatant from LPS treated THP-1 cells was used as a positive control (dotted gray line). Bars represent the mean±SD of at least four samples. (*) indicates statistical
signiﬁcance at pb0.05 as compared to controls.
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sion levels by western blot (Figs. 5A,B). Moreover, HMVEC membrane
permeability signiﬁcantly decreased after TNFα neutralization as dem-
onstrated by TEER reduction from approximately 25 to 12% and FITC-
dextran crossing decrease from 150 to 115% of levels caused by
2KNS4B supernatants without TNFα antibodies (Fig. 5C). Interest-
ingly, when we neutralized TNFα and IL-8 together and treated
HMVEC, we observed an enhanced reduction of adhesion molecule
expression by western blot (Figs. 5A,B) and signiﬁcantly decreased
membrane permeability levels compared to samples treated with
TNFα neutralizing antibodies alone, as measured by TEER (Fig. 5C).
Overall, these data suggest that TNFα and IL-8 may synergistically
increase ICAM-1, VCAM-1 and E-sel expression and induce pheno-
typic changes based on the permeability assay in HMVEC.
A minimum dose of TNFα or IL-8 is required to modulate HMVEC adhesion
molecules or permeability changes
We utilized in-vitro models that mimic a natural infection environ-
ment in order to effectively control for and identify individual immuno-
mediators associated with HMVEC adhesion molecule expression and
permeability. Our previously published data provided immunomedia-
tor concentrations (Kelley et al., 2011) which correspond to the initia-
tion of DHF-associated phenotypes in our HMVEC models. Based on
our HMVEC model treatment dilution strategy of 1:1 (endothelial cell
medium to supernatant from treated THP-1 cells), we were able to
quantitate minimum functional mean concentrations of theimmunomediators required to increase HMVEC permeability
(Table 3). The supernatants, from transfected or infected THP-1
cells, were categorized based on their ability to change HMVEC per-
meability and expressed as pg/mL. Minimum immunomediator levels
able to increase permeability were from supernatants collected at
day 1 after DENV infection, wherein TNFα levels were 14 pg/mL
and IL-8 levels were 483 pg/mL (Table 3). Supernatants having
b9.5 pg/mL of TNFα in combination with b160 pg/mL of IL-8 were
unable to increase permeability. Of note, VEGF was not signiﬁcantly
different for the two groups while IP-10 and IL-6 levels were elevat-
ed in the supernatants that increased permeability even though they
appeared to have no direct effect when TNFα and IL-8 were neutral-
ized (Table 3). Given that clinical samples from DHF/DSS patients
demonstrate elevated levels of TNFα and IL-8, these data and models
may provide ameans to better understand threshold cutoff levels of va-
soactive mediators found during DHF/DSS.
Discussion
Although the mechanisms by which DENV causes severe disease
are not clearly deﬁned, DHF/DSS is associated with elevated levels
of chemokines and cytokines that over-stimulate vascular endothelial
cells leading to expression of adhesion molecules, increased perme-
ability and ultimately irreversible endothelial cell dysfunction (Beynon
et al., 1993; Kurane, 2007). Due to the lack of ideal animal models to
study DHF immunopathogenesis, we used human microvascular endo-
thelial cells to assess alterations associated with DHF/DSS, including
Fig. 5. Neutralization of TNFα and IL-8 secreted by 2KNS4B protein expressing THP-1 cells inhibits HMVEC-activation and -permeability. Neutralizing antibodies against TNFα or
IL-8 were incubated with the supernatant from THP-1 cells expressing 2KNS4B and Western blot, and permeability assays were conducted using the neutralized supernatant.
(A) Western blot analysis of ICAM-1, VCAM-1 and E-sel using HMVEC treated with supernatants from THP-1 cells expressing NS4AB, 2KNS4B, or supernatants from THP-1
cells expressing 2KNS4B incubated with neutralizing antibodies against TNFα or IL-8 or TNFα and IL-8. HMVEC were harvested at 8 h (ICAM-1) or 16 h (VCAM-1 and E-sel)
after treatment. β-actin was employed as an endogenous marker. (B) Percent relative intensity of Western blot test samples compared to relative intensity of positive control
IL-1β. Relative intensity was calculated by dividing the absolute intensity of the adhesion molecule protein band by the absolute intensity of its corresponding β-actin band.
Relative intensities of the positive control were then divided by each sample. (*) indicates a statistically signiﬁcant reduction in relative intensities. (C) HMVEC were seeded
on PET-ﬁbronectin membranes and incubated with supernatants from Fig. 4A and as described in Fig. 1C except without UV-irradiation. The percent change of TEER and
FITC-dextran crossing the membrane was measured. The supernatant from LPS treated THP-1 cells was used as a positive control (dotted gray line). (*) indicates a statistically
signiﬁcant reduction compared to supernatants from THP-1 cells expressing 2KNS4B and (∞) indicates a statistically signiﬁcant reduction in permeability compared to
supernatants from THP-1 cells expressing 2KNS4B and treated with anti-TNFα neutralizing antibody, both at pb0.05. Bars represent the mean±SD of at least four samples.
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ous studies have employed various types of endothelial cells to de-
velop membrane permeability model systems with variable results
(Beynon et al., 1993; Bonner and O'Sullivan, 1998; Carr et al., 2003;
Dewi et al., 2004; Jacobs and Levin, 2002; Talavera et al., 2004).
Additionally, DENV infection or transfection experiments conducted
independently to study the effects of induced immunomediators,
made it difﬁcult to summarize and conclude the role of theseTable 3
Threshold dose levels of chemokines and cytokines that induce HMVEC adhesion molecule
f Day 1 supernatant—mockDay 3 supernatant—mockV5 supernatantNo change in permeability NS3B3(pro) supernatantNS3 supernatant
NS4AB supernatant
2KNS4B supernatant+anti-8+anti-TNFαf Day 1 supernatant—DENV infectedDay 3 supernatant—DENV infectedNS4B supernatantChange in permeability 2KNS4B supernatant2KNS4B supernatant+anti-IL-8 Ab2KNS4B supernatant+anti-TNFα Ab
NS5 supernatant
LPS supernatantimmunomediators in DENV immunopathogenesis (Anderson et al.,
1997; Bifﬂ et al., 1995; Carr et al., 2003; Medin et al., 2005).
Unlike previous reports, in this study we collectively demon-
strate for the ﬁrst time in a single HMVEC experimental system
used to measure both permeability and expression changes of adhe-
sion molecules, that DENV-infected THP-1 cells and transfected THP-1
cells expressing 2KNS4B, produce IL-8 and TNFα levels sufﬁcient
to increase HMVEC permeability, which corresponds to increasedand permeability changes.
IFN VEGF IP-10 TNFα IL-6 IL-8
N.D 1.5 4.3 3.7 b1 21g InfectedND 2.7 8.3 4.2 2.4 49
b1 9.2 6.8 2.6 1.2 101g Transfectedb1 11 5.1 6.8 1.4 109b1 9.0 6.2 9.4 1.1 160b1 10 4.8 8.1 1.2 114
Abs b1 23 33 b1 93 b1
ND 2.5 19 14 1.6 483g Infected1.2 6.0 22 31 54 965
1.7 9.5 22 13 28 550g Transfected3.3 23 33 15 93 1,206b1 23 33 15 93 b1b1 23 33 b1 93 1,206
2.8 20 30 15 55 757
2.5 6.2 28 51 114 1,547 Positive control
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these HMVEC phenotypic changes appear to be caused primarily by
monocyte-derived TNFα, and to a lesser extent IL-8, rather than direct
DENV infection of HMVEC, which is consistent with histopathological
studies demonstrating low or nonexistent infection of endothelial
cells in DHF/DSS patients (Halstead, 1989). By using quantitative
Luminex data, we further demonstrate that a minimum level of TNFα
and IL-8 is required for HMVEC activation or increased permeability,
suggesting that therapies blocking the maturation of NS4B and subse-
quent production of vasoactive mediators, or circulating TNFα and/or
IL-8, may prevent DHF/DSS.
Immunomediators in the supernatants of DENV-infected THP-1 monocytes
increase HMVEC adhesion molecules and permeability
Published data demonstrate that DENV, in the presence of sub-
neutralizing antibodies, infects monocytes and produces immunome-
diators, particularly TNFα, which are responsible for initiating and
sustaining increased vascular endothelial cell permeability (Carr et al.,
2003); whereas TNFα and IL-1β are the primary stimulatory molecules
for ICAM-1, VCAM-1 and E-sel (Anderson et al., 1997; Cardier et al.,
2005; Detmar et al., 1992; Wyble et al., 1996). Anderson et al. demon-
strated that ICAM-1 and VCAM-1 had the greatest expression levels
16 h after HUVEC treatment whereas E-sel appeared to be more tran-
sient, as indicated by its detection at 3 h after treatment (Anderson
et al., 1997). In contrast, we demonstrate increased VCAM-1 and E-sel
at 16 h while ICAM-1 peaked at 8 h after treatment of small vascular
HMVEC. Because vascular endothelial cells are highly organized and
physiologically specialized, experimental differences observed between
HMVEC and HUVEC are most likely due to differences in cell function.
In fact, published data indicate that differences in adhesion molecule
expression levels depend on the vascular cell bed of origin (De Staercke
et al., 2003; Elherik et al., 2003; Gerritsen et al., 1993), emphasizing the
complexity of vascular endothelial cell function in-vivo.
Increased vascular permeability and plasma leakage found during
DHF/DSS pathogenesis occur at defervescence when immunomediator
levels are elevated and viremia has decreased (Iyngkaran et al., 1995;
Kurane and Takasaki, 2001; Leong et al., 2007; Libraty et al., 2002;
Nguyen et al., 2004; Priyadarshini et al., 2010). Although many cell
types can produce immunomediators, supernatants from monocytes
ormonocyte-derivedmacrophages infectedwith DENV or other viruses
that cause systemic hemorrhaging, such as Marburg virus, increase
HUVEC permeability (Carr et al., 2003; Feldmann et al., 1996; Lee et al.,
2006). In this report, we demonstrate that DENV-infected THP-1
monocytes secrete sufﬁcient levels of immunomediators to increase
HMVEC permeability. The observed increase in permeability begins
at 8 h after treatment, when ICAM-1 levels are highest, and peaks
at 24 h after treatment. Interestingly, cytokine-induced permeability
changes occur after adhesion molecule expression and possibly in
part due to ICAM-1 mediated signaling (Marcus et al., 1996; Sumagin
et al., 2008). Persistent over-expression of endothelial cell adhesion
molecules can weaken tight junction proteins (Kanlaya et al., 2009;
Nooteboom et al., 2000; Talavera et al., 2004) and prolong vascular
permeability via cytoskeleton reorganization and endothelial cell shape
change (Clark et al., 2007; Marcus et al., 1996; Sumagin et al., 2008).
One of the primary functions of in-vivo adhesion molecules expression
is leukocyte extravasation from the periphery to interstitial sites of infec-
tion. As adhesion molecules undergo sustained expression during
infection, it is probable that increased levels of inﬁltrating leukocytes
compound vascular endothelial cell permeability as they release vasoac-
tive molecules as part of the innate immune response. In fact, others
demonstrate that increased HUVEC permeability begins at 6 h after
treatment with TNFα, and after maximum expression of another adhe-
sion molecule, endothelial leukocyte adhesion molecule-1 (ELAM-1) at
4 h (Marcus et al., 1996). Also, TNFα alone, albeit ﬁve times the concen-
tration as in the supernatant from LPS-treated THP-1 cells, appears toincrease permeability much more effectively than the supernatants
from DENV-infected THP-1 cells, suggesting a dose dependent effect
on permeability. Together, these data establish that the mediators
present in the supernatants fromDENV-infected THP-1 cells increase
HMVEC permeability, which corresponds with ICAM-1 expression at
8 h after treatment; and that TNFα, with other mediators, may be a
potent inducer of HMVEC phenotypic changes.
DENV-infected HMVEC do not increase expression of ICAM-1, VCAM-1 or
E-sel nor increase permeability levels
DENV and other viruses, such as Ebola virus, Crimean–Congo hem-
orrhagic fever virus and hantavirus, are associated with hemorrhagic
diseases, yet the mechanisms deﬁning their underlying pathology
remain unclear. Ebola virus, a ﬁlovirus, replicates efﬁciently in endo-
thelial cells and produce a destructive infection in-vitro which paral-
lels endothelial cell lysis observed in infected humans (Fisher-Hoch
et al., 1985; Salvaggio and Baddley, 2004). In contrast, DENV is able
to efﬁciently replicate in HUVEC and HMVEC in-vitro but histopath-
ological studies indicate low or nonexistent infection of endothelial
cells as well as little structural damage to capillaries in tissue from
DHF/DSS patients (Bhamarapravati et al., 1967; Halstead, 1988, 1989;
Sahaphong et al., 1980). The paucity of clinical data on infection of
endothelial cells makes it difﬁcult to discern their susceptibility
during progression of DHF/DSS. However, recently published data
indicating absence of infectious DENV particles in moribund mice
exclude a direct virus cytopathic effect and suggest some immuno-
logical disorder due to overstimulation of immune cells possibly by
persistent viral antigens (Tan et al., 2010). Moreover, as we and
others demonstrate, DENV-infected HMVEC do not increase adhe-
sion molecules or permeability (Anderson et al., 1997; Bonner and
O'Sullivan, 1998; Carr et al., 2003; Chareonsirisuthigul et al., 2007)
suggesting a probable role of soluble vasoactive mediators on the
induction of phenotypic changes rather than DENV infection of en-
dothelial cells. Even though both DENV-infected endothelial cells
and mock-infected controls produce fairly high endogenous levels
of IL-8, TNFα was not secreted, suggesting that endothelial cells are
most likely not the source of TNFα. Collectively, based on published
clinical data and our in-vitro data, we postulate that the infection
of immune cells and release of toxic levels of immunomediators
may lead to dysfunctional endothelium including capillary leakage.
Although this explains only part of the conundrum surrounding the
contribution of monocytes and the window period between viremia
and DHF progression, many facts remain to be proven including
the contribution of other cell types during immunomediator produc-
tion and levels of immunomediators from disease onset to DHF/DSS.
Maturation of NS4B in THP-1 cells produces TNFα and IL-8, which
increase HMVEC permeability
Previouslywe demonstrated thatmonocytes expressing the 2KNS4B
protein signiﬁcantly increase immunomediator production compared
to levels induced by NS5. As such, we examined the ability of superna-
tants from monocytes expressing NS proteins to increase adhesion
molecules and permeability. We demonstrated that expression of
either NS5 or 2KNS4B induces sufﬁcient mediators to increase ad-
hesion molecules and permeability, while 2KNS4B has a slightly
greater effect. TNFα is a well-known potent endothelial cell activat-
ing factor, increasing HUVEC adhesion molecule expression (Anderson
et al., 1997) and HMVEC permeability (Carr et al., 2003; Pober and
Cotran, 1990). Other researchers conducting TNFα blocking experiments
demonstrate a signiﬁcant reduction of HMVEC ICAM-1 expression as
induced by dengue patient sera (Cardier et al., 2005). Moreover, two
independent mouse models of dengue infections conﬁrm the associ-
ation of TNFα with disease severity, which was attenuated using
neutralizing TNFα antibodies (Atrasheuskaya et al., 2003; Shresta
334 J.F. Kelley et al. / Virology 422 (2012) 326–337et al., 2005). IL-8 alone can induce permeability at high concentra-
tions (Bifﬂ et al., 1995; Petreaca et al., 2007; Talavera et al., 2004)
as demonstrated during our permeability model optimization exper-
iments. Herein, we demonstrate using neutralizing antibodies that
primarily TNFα, and secondarily IL-8, increase permeability and ad-
hesion molecules. The combined effect appears to be synergistic, as
when we neutralize both TNFα and IL-8 in the supernatants from
THP-1 cells expressing 2KNS4B permeability is signiﬁcantly reduced,
more than the sum of the effect caused by IL-8 and TNFα. This effect
may be due to increased induction of molecules associated with
intracellular signaling pathways but the exact mechanism remains
unclear. Overall, these data suggest that TNFα is primarily respon-
sible for increasing expression of adhesion molecules and perme-
ability, while IL-8 may play a synergistic role (Carr et al., 2003;
Dewi et al., 2004; Dhawan et al., 1997). Moreover, maturation of
NS4B via cleavage of the 2K-signal peptide is sufﬁcient to induce
mediators capable of inducing endothelial cell phenotypic changes
associated with severe DHF/DSS.
A minimum level of TNFα or IL-8 is required to increase HMVEC adhesion
molecules or permeability changes
It has been postulated that elevated immunomediators are re-
sponsible for sustained endothelial cell changes during severe DHF/
DSS. It is plausible that a threshold level of chemokines and cyto-
kines, particularly TNFα and IL-8, is needed to modulate endothelial
cell phenotypic changes during disease progression. Indeed, we demon-
strate that supernatants having at least a two-fold higher level of
TNFα and a four-fold higher level of IL-8, while maintaining similar
levels of VEGF, IP-10 and IL-6, increase membrane permeability.
Moreover, HMVEC treated with high amounts of individual positive
controls, TNFα or IL-8, increase permeability but require over 50 or
8 times higher levels, respectively, than supernatants having lower
levels but combinations of several immunomediators. Low levels of
vasoactive mediators more effectively increase permeability than
individual mediators (Beynon et al., 1993) and TNFα, IFNγ and IL-1
together induce a greater increase in permeability compared to indi-
vidual cytokines (Burke-Gaffney and Keenan, 1993). Also, it is well
known that even low levels of cytokines can induce the production of
other cytokines, suggesting that a complex and interactive immunome-
diator induction network exists which may further facilitate increased
mediators involved in DHF/DSS immunopathogenesis (Kurane et al.,
1994).
Other than the direct TNFα-mediated permeability, TNFα can
activate the production of lipid mediators including platelet-activating
factor (PAF), leukotrienes and prostaglandins, all of which can act as
potent activators of permeability (Lefer, 1989). While control patients'
sera demonstrate mean TNFα levels of 10 pg/mL, sera from DF and
DHF patients reach 220 and 239 pg/mL respectively (Chakravarti
and Kumaria, 2006). Another study from Brazil demonstrates that
sera from DF patients have a mean TNFα level of approximately
28 pg/mL and sera from DHF patients have 128 pg/mL (Braga et al.,
2001). Moreover, circulating soluble TNF receptors have been associ-
ated in children with DHF, correlating with subsequent shock (Bethell
et al., 1998). Given that macrophages, mast cells, natural killer cells,
T- and B-cells and other cells produce TNFα, we are unable to corre-
late clinical estimates. However, our data and others suggest that
reduction of vasoactive mediators, speciﬁcally TNFα, in DENV-infected
patients may minimize the risk of DHF/DSS progression.
Conclusions
Although themechanisms by which DENV causes severe disease are
not clearly deﬁned, DHF/DSS is associated with elevated levels of TNFα
and other chemokines and cytokines, secreted in part by infected
monocytes, that can cause irreversible endothelial cell dysfunction(Beynon et al., 1993; Kurane, 2007). We have previously demonstrated
that DENV, primarily via maturation of NS4B and sequential processing
of 2KNS4B, induces DHF-associated immunomediators in THP-1 cells
(Kelley et al., 2011). Herein we demonstrate that immunomediator
levels induced by 2KNS4B are sufﬁcient to initiate DHF-associated phe-
notypic changes, includingHMVECpermeability and adhesionmolecule
expression changes. Also, we demonstrate that HMVEC phenotypic
changes appear to be caused primarily by TNFα (and IL-8) rather than
direct DENV infection of HMVEC. It appears that a minimum level of
TNFα and IL-8 is required during HMVEC activation or permeability.
Based on these data, antiviral therapies that block the maturation of
NS4B or TNFα inhibitors that reduce elevated levels of TNFα may
prevent the progression of DHF/DSS.
Materials and methods
Virus, cell culture, supernatants from THP-1 cells and other reagents
We employed a low passage DENV-2 NGC strain (obtained from
Dr. Duane Gubler at the University of Hawaii at Manoa) propagated
in C6/36 cells to infect primary HMVEC and Vero (monkey kidney
epithelial) cells (Kelley et al., 2011). For mock-infection, control virus
was inactivated by UV-light irradiation for 10 min. For the endothelial
cell activation and permeability experiments, we employed primary
HMVEC purchased from the Lonza Group Ltd. (Basal, Switzerland). As
per the manufacturer's technical sheet, HMVEC stain positive for acety-
lated LDL and von Willebrand's (Factor VIII) antigen and stain negative
for smooth muscle α-actin. HMVEC were received at passage 3 and
grown in endothelial cell growthmedium EGM-2-MV and SingleQuot®
growth supplements including, bovine brain extractwith heparin, hEGF,
hydrocortisone, gentamicin, amphotericin B, and 5% fetal bovine serum
(FBS) (Lonza). All experimentswere conducted using HMVEC passage 5.
The Vero cells were purchased from the American Type Culture
Collection (ATCC, Rockville,MD) andmaintained inminimumessential
medium Eagle (MEME) supplemented with 10% heat-inactivated FBS,
1% penicillin/streptomycin and 10 μg/mL gentamicin (Gibco Labs,
Grand Island, NY). Both cell types were incubated at 37 °C in a 5% CO2
atmosphere and the growth media was changed every 2 or 3 days.
The supernatants used to treat the endothelial cells were collected
from THP-1 cells of monocytic lineage (ATCC) either infected with
DENV at MOI-1, treated with 1 μg/mL of LPS for 1 h, washed and incu-
bated with fresh growth media until collection after 24 h, or cells
expressing individual DENV nonstructural proteins (NS) as described
previously (Kelley et al., 2011). For positive controls we used recombi-
nant TNFα, IL-8, or IL-1β proteins and to neutralize immunomedia-
tors, we used antibodies against TNFα and IL-8 (R&D Systems,
Minneapolis, MN). For experiments involving neutralizing anti-
bodies, cells were washed, and media was changed to 10% heat-
inactivated FBS DMEM before antibody treatment.
Infection of HMVEC and Vero cells
The DENV2 NGC strain was used to infect 1×106 HMVEC or Vero
cells in 12-well tissue culture plates or 1×105 HMVEC cells on
ﬁbronectin-coated polyethylene terephthalate (PET) 24-well insert
membranes at MOI-1. After 1.5 h at 37 °C and 5% CO2, the cells
were washed twice with fresh growth media and further cultured
with growth medium. For the mock-infected controls, we inoculated
HMVEC with UV-inactivated DENV, as described previously (Verma
et al., 2009). As a positive control for adhesion molecule experi-
ments, 1×106 HMVEC were incubated with 200 pg of IL-1β for 1 h,
washed and incubated with fresh growth media until collection at
8 h after incubation for detection of ICAM-1 and 16 h after incuba-
tion for detection of VCAM-1 and E-sel. Every 24 h, cells and super-
natants were collected while remaining cells were replenished
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was conﬁrmed by plaque assay as described below.
Plaque assay
To determine the amount of infectious virus released from DENV-
infected THP-1 cells, plaque assay was conducted using Vero cell mono-
layers as described previously (Lambeth et al., 2005). Brieﬂy, 2.5×105
Vero cells per well were seeded in 6-well culture plates (Corning,
Lowell, MA) and incubated for 2 to 3 days until conﬂuent. Supernatants
from DENV-infected THP-1 cells were serially diluted using 10-fold
dilutions in Dulbecco's Modiﬁed Eagles Medium (DMEM) (Gibco
Labs) supplemented with 10% FBS and 100 μL of each dilution was
added to each well of the Vero cells followed by incubation at 37 °C
and 5% CO2 for 1 h with rocking every 15 min. 3 mL of primary nutri-
ent agar containing 1% SeaKem® LE agarose (Lonza, Walkersville,
MD) was added to each well and the plates were incubated for
5 days. 3 mL of secondary nutrient agar (primary agar containing
1% neutral red) was added to each well and the plates were incubat-
ed for an additional 2 days before counting plaques and calculating
viral titers (Kelley et al., 2011; Lambeth et al., 2005). Titers were
expressed as plaque forming units (PFU)/mL.
Quantitative real-time RT-PCR (qRT-PCR)
Total cellular RNA was extracted as per manufacturers' protocol
(RNeasy® Plus kit with RNase-Free DNase, Qiagen) from DENV-
infected HMVEC harvested at different time points. cDNA was synthe-
sized using 1 μg of RNA using the BioRad iScript® kit in a 20 μL reaction
volume. BioRad iCycler iQ™Multicolor Real-Time PCR Detection System
was employed to conduct qRT-PCR for quantitation of DENV copy num-
bers or ICAM-1, VCAM-1 and E-sel genes using Bio-Rad iQ™ SYBR®
Green Supermix, 2 μL of 1:3 diluted cDNA, and 10 pmol each of forward
and reverse primers (Table 4) in a ﬁnal reaction volume of 20 μL. Ther-
mal cycling reactions for both DENV and adhesion molecule ampliﬁca-
tions were initiated with a denaturing step of 4 min at 95 °C, followed
by 40 cycles of 95 °C (30 s) and a range of 55–60 °C (30 s) depending
on the Tm (Table 4). A standard curve to measure DENV copies was
developed from 10-fold serial dilutions of linear DENV gene having
known concentrations to quantitate the dynamic range of detection of
102 to 108 copies per μg of RNA. Host cellular gene changes relative toTable 4
Primers employed for the analysis of DENV and host genes by qRT-PCR.
Gene
(GenBank no.)





Forward CAATATGCTGAAACGCGAGAG 60 167
Reverse CATCTATTCAGAATCCCTGCT
ICAM-1 (NM_002162)b
Forward AGCGGCAGTTACCATGTTAGGG 58 146
Reverse GGCTTTATTGGTGCGGAATCTGA
VCAM-1 (BC068490)
Forward TGCTGCTCAGATTGGAGACTC 55 113
Reverse TCCTCACCTTCCCGCTCAG
E-selectin (NM_000450)b
Forward TGAGACAGAGGCAGCAGTG 57 199
Reverse CCGTGGAGGTGTTGTAAGAC
GAPDH (BC025925)b
Forward AGTTAGCCGCATCTTCTTTTGC 57 96
Reverse CAATACGACCAAATCCGTTGACT
a Real-time PCR primers to determine DENV2 NGC copy numbers.
b Real-timeRT-PCR primers to amplify adhesionmolecule genes orGAPDH endogenous
control.the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeep-
ing gene were determined as previously described (Kelley et al., 2011;
Verma et al., 2006). Primers used to measure cellular gene changes are
listed in Table 4.
In-vitro permeability model
We constructed the in-vitro permeability model using Millipore
Biocoat® cell culture inserts with ﬁbronectin-coated PET membranes
with 3 μm pores and 0.33 cm2 diameter (BD Bioscience, Bedford, MA)
as described previously (Verma et al., 2009). Brieﬂy, after rehydrating
the inserts in warm culture medium, 1×105 HMVEC in 250 μL fresh
medium were seeded in the upper chamber and 1 mL medium was
added to the lower chamber of the 24-well insert plate. Further, the
inserts were incubated at 37 °C in a 5% CO2 atmosphere. The integrity
of the membranes was measured from days 3 to 15 after seeding
HMVEC by using transendothelial electrical resistance (TEER) and
FITC-dextran (4 kDa mol. wt., Sigma) permeability assays. We choose
4 kDa FITC-dextran based on previous research using primary human
brain microvascular endothelial cells (Verma et al., 2009). Similarly,
TEER was measured using the Endohm chamber (World Precisions,
Saratoga, FL) and permeability was calculated as per manufacturers'
protocol (Verma et al., 2009). FITC-dextran crossing the membrane
was measured by adding to the upper chamber 250 μL of 100 μg/mL
FITC-dextran medium with or without either 0.5 ng/mL of TNFα or
2.5 ng/mL IL-8. Supernatants, 250 μL, from the THP-1 cells were
added to the upper chamber and incubated with the HMVEC model
at a 1:1 dilution of supernatant in EBM plus 100 μg/mL FITC-dextran
for 1.5 h at 37 °C in a 5% CO2. Duplicate samples of 150 μL of medium
was aliquoted from the lower chamber into a 96-well plate to mea-
sure the ﬂuorescence of transmigrated FITC-dextran on a Victor
1420 (PerkinElmer Life Sciences and Analytical Sciences, Boston,
MA) with excitation at 485 nm and emission at 535 nm. The FITC-
dextran migration across the membrane was calculated as a percent-
age of the total amount initially added in the upper chamber and data
was calculated as a percent change to untreated control membranes.
For DENV infection experiments, HMVEC in the upper chamber were
infected with either UV-treated DENV or DENV at MOI-1 beginning at
day 6 after seeding, and TEER and FITC-dextran permeability were
measured as previously described (Verma et al., 2009).
Cytokine quantitation and conversion into dose treatment values
IL-6, IL-8, TNFα, and IFNγ were measured in the supernatants of
DENV-infected HMVEC using a Milliplex human cytokine and chemo-
kine 4-plex immunoassay kit (Millipore Corp., Billerica, MA) together
with the Luminex® 100™ System (Luminex, Austin, TX) to determine
mean ﬂuorescent intensities (MFI) as recommended by the manufac-
turers. Protein concentrations were calculated from MFI data using
10-fold serially-diluted standards and Bead View analysis software
version 1.0.4 (Millipore). The minimum detectable concentrations
were 0.4 pg/mL for IL-6, 0.3 pg/mL for IL-8, 0.2 pg/mL for TNFα and
0.4 pg/mL for IFNγ. Given that we diluted THP-1 supernatants 1:1 in
endothelial cell medium, we divided the given concentrations by
half to obtain minimum dose treatment concentration levels in pg/
mL (Table 3).
Western blot
Total cellular protein extracts were prepared from HMVEC cells ei-
ther 8 h after treatment (ICAM-1), 16 h after treatment (VCAM-1 and
E-sel) or at otherwise indicated time point. Cells were washed once
with cold PBS and extracted with 200 μL of M-PER mammalian pro-
tein extraction buffer (Thermo Scientiﬁc, Rockford, IL) containing
EDTA-free complete protease inhibitor cocktail (Roche, Indianapolis,
IN). 50 μg in 20 μL of total protein was fractionated on a 4–12%
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Hercules, CA) and then transferred onto a 0.2 μm nitrocellulose
ﬁlter (Bio-Rad Laboratories) as previously described (Verma et al.,
2006). Nonspeciﬁc binding sites were blocked using 5% FBS in 1x Tris
buffered saline (TBS) with 0.1% Tween (TBST). Membranes were incu-
bated with primary DENV envelope antibody (courtesy of Dr. Wei-Kung
Wang, University of Hawaii, detection ~52 kDa) or ICAM-1 mouse
monoclonal (band size ~90 kDa), VCAM-1 rabbit polyclonal (band
size ~110 kDa), E-sel mouse monoclonal (band size ~150 kDa) or
β-actin IgG antibodies (Santa Cruz Biotechnology, Santa Cruz, CA)
at a 1:1000 dilution and incubated at 4 °C overnight followed by
incubation with a secondary antibody conjugated to HRP (dilution
1:5000) at room temperature for 1 h. Protein bands were detected
with enhanced chemiluminescence (Amersham ECL, GE Health-
care Limited, Buckinghamshire, UK) on Amersham ECL Hyperﬁlm
(Kodak, Rochester, NY). To determine the relative intensity (RI)
of protein bands, the absolute intensity of the adhesion molecule
protein band was divided by the absolute intensity of its corre-
sponding β-actin band. Absolute intensities were calculated using
Photoshop by multiplying the given pixel value and mean intensi-
ty of selected bands as previously described (Luhtala and Parker,
2009).
Cell viability assay
To determine the cell viability, control HMVEC or HMVEC were
treated with TNFα (0.5 ng/mL), IL-8 (2.5 ng/mL), IL-1β (200 pg/
mL) or THP-1 supernatant (1:1 dilution with EBM) or were infected
with DENV MOI-1. Brieﬂy, 2×104 HMVEC were seeded on 96-well
tissue culture plates and after 3 days, triplicate wells of conﬂuent
monolayer were incubated with 200 μL of each of the aforemen-
tioned treatments for 8, 16, 24 or 48 h, and cell viability was mea-
sured using the CellTiter96 AQueous One Solution Cell Proliferation
Assay (Promega, Madison, WI) kit as per the manufacturers' proto-
col (Verma et al., 2008).
Statistical analysis
Statistical tests, including paired and unpaired Student's t-tests,
were conducted for qRT-PCR and cytokine and chemokine immuno-
assay using GraphPad InStat version 5.0 (GraphPad software, San
Diego, CA). Values were expressed as mean±SD of at least two inde-
pendent observations. P values of b0.05 were considered signiﬁcant.
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.virol.2011.10.030.
Acknowledgments
We are grateful to Dr. Wei Kung Wang from the Department of
Tropical Medicine, Medical Microbiology and Pharmacology at the
University of Hawaii for providing the pCprM/pCRII-TOPO DENV
plasmid DNA used as a template for the qRT-PCR standards. We
thank the staff and students of the Retrovirology Research Laborato-
ry and the Department of Tropical Medicine, Medical Microbiology
and Pharmacology for technical assistance. This work was submitted
by JFK to the University of Hawaii at Manoa as part of his doctoral
thesis project.
This work was supported in part by institutional funds and grants
from the Department of Defense (W8IXWH0720073), and Centers of
Biomedical Research Excellence (P20RR018727) and Research Cen-
ters in Minority Institutions Program (G12RR003061), National
Center for Research Resources, National Institutes of Health. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. The authors
declare no competing interests.References
Anderson, R., Wang, S., Osiowy, C., Issekutz, A.C., 1997. Activation of endothelial cells
via antibody-enhanced dengue virus infection of peripheral blood monocytes. J.
Virol. 71 (6), 4226–4232.
Andrews, B.S., Theoﬁlopoulos, A.N., Peters, C.J., Loskutoff, D.J., Brandt, W.E., Dixon, F.J.,
1978. Replication of dengue and junin viruses in cultured rabbit and human
endothelial cells. Infect. Immun. 20 (3), 776–781.
Arevalo, M.T., Simpson-Haidaris, P.J., Kou, Z., Schlesinger, J.J., Jin, X., 2009. Primary
human endothelial cells support direct but not antibody-dependent enhancement
of dengue viral infection. J. Med. Virol. 81 (3), 519–528.
Atrasheuskaya, A., Petzelbauer, P., Fredeking, T.M., Ignatyev, G., 2003. Anti-TNF
antibody treatment reduces mortality in experimental dengue virus infection.
FEMS Immunol. Med. Microbiol. 35 (1), 33–42.
Avirutnan, P., Malasit, P., Seliger, B., Bhakdi, S., Husmann, M., 1998. Dengue virus
infection of human endothelial cells leads to chemokine production, complement
activation, and apoptosis. J. Immunol. 161 (11), 6338–6346.
Bethell, D.B., Flobbe, K., Cao, X.T., Day, N.P., Pham, T.P., Buurman, W.A., Cardosa, M.J.,
White, N.J., Kwiatkowski, D., 1998. Pathophysiologic and prognostic role of
cytokines in dengue hemorrhagic fever. J. Infect. Dis. 177 (3), 778–782.
Beynon, H.L., Haskard, D.O., Davies, K.A., Haroutunian, R., Walport, M.J., 1993. Combinations
of low concentrations of cytokines and acute agonists synergize in increasing the
permeability of endothelial monolayers. Clin. Exp. Immunol. 91 (2), 314–319.
Bhamarapravati, N., Tuchinda, P., Boonyapaknavik, V., 1967. Pathology of Thailand
haemorrhagic fever: a study of 100 autopsy cases. Ann. Trop. Med. Parasitol. 61
(4), 500–510.
Bifﬂ, W.L., Moore, E.E., Moore, F.A., Carl, V.S., Franciose, R.J., Banerjee, A., 1995. Interleu-
kin-8 increases endothelial permeability independent of neutrophils. J. Trauma 39
(1), 98–102 (discussion 102–3).
Bonner, S.M., O'Sullivan, M.A., 1998. Endothelial cell monolayers as a model system to
investigate dengue shock syndrome. J. Virol. Methods 71 (2), 159–167.
Bozza, F.A., Cruz, O.G., Zagne, S.M., Azeredo, E.L., Nogueira, R.M., Assis, E.F., Bozza, P.T.,
Kubelka, C.F., 2008. Multiplex cytokine proﬁle from dengue patients: MIP-1beta
and IFN-gamma as predictive factors for severity. BMC Infect. Dis. 8, 86.
Braga, E.L., Moura, P., Pinto, L.M., Ignacio, S.R., Oliveira, M.J., Cordeiro, M.T., Kubelka, C.F.,
2001. Detection of circulant tumornecrosis factor-alpha, soluble tumornecrosis factor
p75 and interferon-gamma in Brazilian patients with dengue fever and dengue
hemorrhagic fever. Mem. Inst. Oswaldo Cruz 96 (2), 229–232.
Bunyaratvej, A., Butthep, P., Yoksan, S., Bhamarapravati, N., 1997. Dengue viruses
induce cell proliferation and morphological changes of endothelial cells. Southeast
Asian J. Trop. Med. Public Health 28 (Suppl 3), 32–37.
Burke-Gaffney, A., Keenan, A.K., 1993. Modulation of human endothelial cell perme-
ability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis
factor-alpha and interferon-gamma. Immunopharmacology 25 (1), 1–9.
Cardier, J.E., Marino, E., Romano, E., Taylor, P., Liprandi, F., Bosch, N., Rothman, A.L.,
2005. Proinﬂammatory factors present in sera from patients with acute dengue
infection induce activation and apoptosis of human microvascular endothelial
cells: possible role of TNF-alpha in endothelial cell damage in dengue. Cytokine
30 (6), 359–365.
Carr, J.M., Hocking, H., Bunting, K., Wright, P.J., Davidson, A., Gamble, J., Burrell, C.J., Li,
P., 2003. Supernatants from dengue virus type-2 infected macrophages induce
permeability changes in endothelial cell monolayers. J. Med. Virol. 69 (4), 521–528.
Chakravarti, A., Kumaria, R., 2006. Circulating levels of tumour necrosis factor-alpha
and interferon-gamma in patients with dengue and dengue haemorrhagic fever
during an outbreak. Indian J. Med. Res. 123 (1), 25–30.
Chang, C.S., Harn, M.R., Nimmannitya, S., 1990. Clinical observation of 15 Thai children
with dengue hemorrhagic fever. Gaoxiong Yi Xue Ke Xue Za Zhi 6 (3), 131–136.
Chareonsirisuthigul, T., Kalayanarooj, S., Ubol, S., 2007. Dengue virus (DENV) antibody-
dependent enhancement of infection upregulates the production of anti-inﬂammatory
cytokines, but suppresses anti-DENV free radical and pro-inﬂammatory cytokine
production, in THP-1 cells. J. Gen. Virol. 88 (Pt 2), 365–375.
Chen, L.C., Shyu, H.W., Lin, H.M., Lei, H.Y., Lin, Y.S., Liu, H.S., Yeh, T.M., 2009. Dengue
virus induces thrombomodulin expression in human endothelial cells and
monocytes in vitro. J. Infect. 58 (5), 368–374.
Clark, P.R., Manes, T.D., Pober, J.S., Kluger, M.S., 2007. Increased ICAM-1 expression
causes endothelial cell leakiness, cytoskeletal reorganization and junctional
alterations. J. Invest. Dermatol. 127 (4), 762–774.
De Staercke, C., Phillips, D.J., Hooper,W.C., 2003. Differential responses of human umbilical
and coronary artery endothelial cells to apoptosis. Endothelium 10 (2), 71–78.
Detmar, M., Tenorio, S., Hettmannsperger, U., Ruszczak, Z., Orfanos, C.E., 1992. Cytokine
regulation of proliferation and ICAM-1 expression of human dermal microvascular
endothelial cells in vitro. J. Invest. Dermatol. 98 (2), 147–153.
Dewi, B.E., Takasaki, T., Kurane, I., 2004. In vitro assessment of human endothelial cell
permeability: effects of inﬂammatory cytokines and dengue virus infection. J. Virol.
Methods 121 (2), 171–180.
Dewi, B.E., Takasaki, T., Kurane, I., 2008. Peripheral blood mononuclear cells increase
the permeability of dengue virus-infected endothelial cells in association with
downregulation of vascular endothelial cadherin. J. Gen. Virol. 89 (Pt 3), 642–652.
Dhawan, S., Singh, S., Aggarwal, B.B., 1997. Induction of endothelial cell surface
adhesion molecules by tumor necrosis factor is blocked by protein tyrosine
phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur. J.
Immunol. 27 (9), 2172–2179.
Durbin, A.P., Vargas, M.J., Wanionek, K., Hammond, S.N., Gordon, A., Rocha, C., Balmaseda,
A., Harris, E., 2008. Phenotyping of peripheral blood mononuclear cells during acute
dengue illness demonstrates infection and increased activation of monocytes in
severe cases compared to classic dengue fever. Virology 376 (2), 429–435.
337J.F. Kelley et al. / Virology 422 (2012) 326–337Elherik, K.E., Khan, F., Belch, J.J., 2003. Differences in endothelial function and vascular
reactivity between Scottish and Arabic populations. Scott. Med. J. 48 (3), 85–87.
Feldmann, H., Bugany, H., Mahner, F., Klenk, H.D., Drenckhahn, D., Schnittler, H.J., 1996.
Filovirus-induced endothelial leakage triggered by infectedmonocytes/macrophages.
J. Virol. 70 (4), 2208–2214.
Fisher-Hoch, S.P., Platt, G.S., Neild, G.H., Southee, T., Baskerville, A., Raymond, R.T.,
Lloyd, G., Simpson, D.I., 1985. Pathophysiology of shock and hemorrhage in a
fulminating viral infection (Ebola). J. Infect. Dis. 152 (5), 887–894.
Gerritsen, M.E., Niedbala, M.J., Szczepanski, A., Carley, W.W., 1993. Cytokine activation
of human macro- and microvessel-derived endothelial cells. Blood Cells 19 (2),
325–339 (discussion 340–2).
Gibbs, L.S., Lai, L., Malik, A.B., 1990. Tumor necrosis factor enhances the neutrophil-
dependent increase in endothelial permeability. J. Cell. Physiol. 145 (3), 496–500.
Halstead, S.B., 1988. Pathogenesis of dengue: challenges to molecular biology. Science
239 (4839), 476–481.
Halstead, S.B., 1989. Antibody, macrophages, dengue virus infection, shock, and hemor-
rhage: a pathogenetic cascade. Rev. Infect. Dis. 11 (Suppl. 4), S830–S839.
Huang, Y.H., Lei, H.Y., Liu, H.S., Lin, Y.S., Liu, C.C., Yeh, T.M., 2000. Dengue virus infects
human endothelial cells and induces IL-6 and IL-8 production. Am. J. Trop. Med.
Hyg. 63 (1–2), 71–75.
Iyngkaran, N., Yadav, M., Sinniah, M., 1995. Augmented inﬂammatory cytokines in
primary dengue infection progressing to shock. Singapore Med. J. 36 (2), 218–221.
Jacobs, M., Levin, M., 2002. An improved endothelial barrier model to investigate
dengue haemorrhagic fever. J. Virol. Methods 104 (2), 173–185.
Jessie, K., Fong, M.Y., Devi, S., Lam, S.K., Wong, K.T., 2004. Localization of dengue virus in
naturally infected human tissues, by immunohistochemistry and in situ hybridiza-
tion. J. Infect. Dis. 189 (8), 1411–1418.
Kanlaya, R., Pattanakitsakul, S.N., Sinchaikul, S., Chen, S.T., Thongboonkerd, V., 2009.
Alterations in actin cytoskeletal assembly and junctional protein complexes in
human endothelial cells induced by dengue virus infection and mimicry of leuko-
cyte transendothelial migration. J. Proteome Res. 8 (5), 2551–2562.
Kelley, J.F., Kaufusi, P.H., Volper, E.M., Nerurkar, V.R., 2011. Maturation of dengue virus
nonstructural protein 4B in monocytes enhances production of dengue hemor-
rhagic fever-associated chemokines and cytokines. Virology 418 (1), 27–39.
Khongphatthanayothin, A., Phumaphuti, P., Thongchaiprasit, K., Poovorawan, Y., 2006.
Serum levels of sICAM-1 and sE-selectin in patients with dengue virus infection.
Jpn. J. Infect. Dis. 59 (3), 186–188.
Koraka, P., Murgue, B., Deparis, X., Van Gorp, E.C., Setiati, T.E., Osterhaus, A.D., Groen, J.,
2004. Elevation of soluble VCAM-1 plasma levels in children with acute dengue
virus infection of varying severity. J. Med. Virol. 72 (3), 445–450.
Kuno, G., Bailey, R.E., 1994. Cytokine responses to dengue infection among Puerto Rican
patients. Mem. Inst. Oswaldo Cruz 89 (2), 179–182.
Kurane, I., 2007. Dengue hemorrhagic fever with special emphasis on immunopatho-
genesis. Comp. Immunol. Microbiol. Infect. Dis. 30 (5–6), 329–340.
Kurane, I., Takasaki, T., 2001. Dengue fever and dengue haemorrhagic fever: challenges
of controlling an enemy still at large. Rev. Med. Virol. 11 (5), 301–311.
Kurane, I., Rothman, A.L., Livingston, P.G., Green, S., Gagnon, S.J., Janus, J., Innis, B.L.,
Nimmannitya, S., Nisalak, A., Ennis, F.A., 1994. Immunopathologic mechanisms of
dengue hemorrhagic fever and dengue shock syndrome. Arch. Virol. Suppl. 9, 59–64.
Lambeth, C.R., White, L.J., Johnston, R.E., de Silva, A.M., 2005. Flow cytometry-based
assay for titrating dengue virus. J. Clin. Microbiol. 43 (7), 3267–3272.
Lee, Y.R., Liu, M.T., Lei, H.Y., Liu, C.C., Wu, J.M., Tung, Y.C., Lin, Y.S., Yeh, T.M., Chen, S.H.,
Liu, H.S., 2006. MCP-1, a highly expressed chemokine in dengue haemorrhagic
fever/dengue shock syndrome patients, may cause permeability change, possibly
through reduced tight junctions of vascular endothelium cells. J. Gen. Virol. 87
(Pt 12), 3623–3630.
Lefer, A.M., 1989. Signiﬁcance of lipid mediators in shock states. Circ. Shock 27 (1), 3–12.
Leong, A.S., Wong, K.T., Leong, T.Y., Tan, P.H., Wannakrairot, P., 2007. The pathology of
dengue hemorrhagic fever. Semin. Diagn. Pathol. 24 (4), 227–236.
Libraty, D.H., Endy, T.P., Houng, H.S., Green, S., Kalayanarooj, S., Suntayakorn, S.,
Chansiriwongs, W., Vaughn, D.W., Nisalak, A., Ennis, F.A., Rothman, A.L., 2002.
Differing inﬂuences of virus burden and immune activation on disease severity in
secondary dengue-3 virus infections. J. Infect. Dis. 185 (9), 1213–1221.
Luhtala, N., Parker, R., 2009. LSM1 over-expression in Saccharomyces cerevisiae depletes
U6 snRNA levels. Nucleic Acids Res. 37 (16), 5529–5536.
Malavige, G.N., Fernando, S., Fernando, D.J., Seneviratne, S.L., 2004. Dengue viral infec-
tions. Postgrad. Med. J. 80 (948), 588–601.
Marcus, B.C., Wyble, C.W., Hynes, K.L., Gewertz, B.L., 1996. Cytokine-induced increases
in endothelial permeability occur after adhesion molecule expression. Surgery 120
(2), 411–416 (discussion 416–7).
Medin, C.L., Fitzgerald, K.A., Rothman, A.L., 2005. Dengue virus nonstructural protein NS5
induces interleukin-8 transcription and secretion. J. Virol. 79 (17), 11053–11061.
Molet, S., Gosset, P., Vanhee, D., Tillie-Leblond, I., Wallaert, B., Capron, M., Tonnel, A.B.,
1998. Modulation of cell adhesion molecules on human endothelial cells by
eosinophil-derived mediators. J. Leukoc. Biol. 63 (3), 351–358.Murgue, B., 2010. Severe dengue: questioning the paradigm. Microbes Infect. 12 (2),
113–118.
Nguyen, T.H., Lei, H.Y., Nguyen, T.L., Lin, Y.S., Huang, K.J., Le, B.L., Lin, C.F., Yeh, T.M., Do,
Q.H., Vu, T.Q., Chen, L.C., Huang, J.H., Lam, T.M., Liu, C.C., Halstead, S.B., 2004.
Dengue hemorrhagic fever in infants: a study of clinical and cytokine proﬁles. J.
Infect. Dis. 189 (2), 221–232.
Nooteboom, A., Hendriks, T., Otteholler, I., van der Linden, C.J., 2000. Permeability
characteristics of human endothelial monolayers seeded on different extracellular
matrix proteins. Mediators Inﬂamm. 9 (5), 235–241.
Petreaca,M.L., Yao, M., Liu, Y., Defea, K., Martins-Green,M., 2007. Transactivation of vascu-
lar endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for
IL-8/CXCL8-induced endothelial permeability. Mol. Biol. Cell 18 (12), 5014–5023.
Pober, J.S., Cotran, R.S., 1990. Cytokines and endothelial cell biology. Physiol. Rev. 70
(2), 427–451.
Priyadarshini, D., Gadia, R.R., Tripathy, A., Gurukumar, K.R., Bhagat, A., Patwardhan, S.,
Mokashi, N., Vaidya, D., Shah, P.S., Cecilia, D., 2010. Clinical ﬁndings and pro-
inﬂammatory cytokines in dengue patients in Western India: a facility-based
study. PLoS One 5 (1), e8709.
Raghupathy, R., Chaturvedi, U.C., Al-Sayer, H., Elbishbishi, E.A., Agarwal, R., Nagar, R., Kapoor,
S., Misra, A., Mathur, A., Nusrat, H., Azizieh, F., Khan, M.A., Mustafa, A.S., 1998. Elevated
levels of IL-8 in dengue hemorrhagic fever. J. Med. Virol. 56 (3), 280–285.
Sahaphong, S., Riengrojpitak, S., Bhamarapravati, N., Chirachariyavej, T., 1980. Electron
microscopic study of the vascular endothelial cell in dengue hemorrhagic fever.
Southeast Asian J. Trop. Med. Public Health 11 (2), 194–204.
Salvaggio, M.R., Baddley, J.W., 2004. Other viral bioweapons: Ebola and Marburg
hemorrhagic fever. Dermatol. Clin. 22 (3), 291–302 (vi).
Shresta, S., Sharar, K.L., Prigozhin, D.M., Snider, H.M., Beatty, P.R., Harris, E., 2005.
Critical roles for both STAT1-dependent and STAT1-independent pathways in the
control of primary dengue virus infection in mice. J. Immunol. 175 (6), 3946–3954.
Srichaikul, T., Nimmannitya, S., 2000. Haematology in dengue and dengue haemorrhagic
fever. Baillieres Best Pract. Res. Clin. Haematol. 13 (2), 261–276.
Srikiatkhachorn, A., 2009. Plasma leakage in dengue haemorrhagic fever. Thromb.
Haemost. 102 (6), 1042–1049.
Sumagin, R., Lomakina, E., Sarelius, I.H., 2008. Leukocyte-endothelial cell interactions
are linked to vascular permeability via ICAM-1-mediated signaling. Am. J. Physiol.
Heart Circ. Physiol. 295 (3), H969–H977.
Talavera, D., Castillo, A.M., Dominguez, M.C., Gutierrez, A.E., Meza, I., 2004. IL8 release,
tight junction and cytoskeleton dynamic reorganization conducive to permeability
increase are induced by dengue virus infection of microvascular endothelial
monolayers. J. Gen. Virol. 85 (Pt 7), 1801–1813.
Tan, G.K., Ng, J.K., Trasti, S.L., Schul, W., Yip, G., Alonso, S., 2010. A non mouse-adapted
dengue virus strain as a newmodel of severe dengue infection in AG129mice. PLoS
Negl. Trop. Dis. 4 (4), e672.
Ubol, S., Chareonsirisuthigul, T., Kasisith, J., Klungthong, C., 2008. Clinical isolates of
dengue virus with distinctive susceptibility to nitric oxide radical induce differential
gene responses in THP-1 cells. Virology 376 (2), 290–296.
Vaughan, G., Gonzalez-Hernandez, Y., Gudino, J.C., Olivera, H., Landa-Piedra, A., Escobar-
Gutierrez, A., 2008. An alternative method for the synthesis of competitor RNA
transcripts useful for speciﬁc detection and quantitation of dengue virus serotype 2
genome and replicative intermediate RNA. J. Virol. Methods 152 (1–2), 72–76.
Verma, S., Ziegler, K., Ananthula, P., Co, J.K., Frisque, R.J., Yanagihara, R., Nerurkar, V.R.,
2006. JC virus induces altered patterns of cellular gene expression: interferon-
inducible genes as major transcriptional targets. Virology 345 (2), 457–467.
Verma, S., Molina, Y., Lo, Y.Y., Cropp, B., Nakano, C., Yanagihara, R., Nerurkar, V.R., 2008.
In vitro effects of selenium deﬁciency on West Nile virus replication and cytopath-
ogenicity. Virol. J. 5, 66.
Verma, S., Lo, Y., Chapagain, M., Lum, S., Kumar, M., Gurjav, U., Luo, H., Nakatsuka, A.,
Nerurkar, V.R., 2009. West Nile virus infection modulates human brain microvascular
endothelial cells tight junction proteins and cell adhesion molecules: transmigration
across the in vitro blood–brain barrier. Virology 385 (2), 425–433.
Vitarana, T., de Silva, H.,Withana, N., Gunasekera, C., 1991. Elevated tumour necrosis factor
in dengue fever and dengue haemorrhagic fever. Ceylon Med. J. 36 (2), 63–65.
Warke, R.V., Xhaja, K., Martin, K.J., Fournier, M.F., Shaw, S.K., Brizuela, N., de Bosch, N.,
Lapointe, D., Ennis, F.A., Rothman, A.L., Bosch, I., 2003. Dengue virus induces novel
changes in gene expression of human umbilical vein endothelial cells. J. Virol. 77
(21), 11822–11832.
WHO, 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment Prevention and
Control. WHO, Geneva.
World Health Organization, 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment
Prevention and Control. WHO, Geneva.
World Health Organization, 2009. Dengue and dengue haemorrhagic fever. (Fact sheet
#117 ed.) WHO Media Centre, Geneva.
Wyble, C.W., Desai, T.R., Clark, E.T., Hynes, K.L., Gewertz, B.L., 1996. Physiologic
concentrations of TNFalpha and IL-1beta released from reperfused human intestine
upregulate E-selectin and ICAM-1. J. Surg. Res. 63 (1), 333–338.
